Advertisement
UK markets open in 4 hours 19 minutes
  • NIKKEI 225

    38,335.30
    +783.14 (+2.09%)
     
  • HANG SENG

    17,057.69
    +228.76 (+1.36%)
     
  • CRUDE OIL

    83.31
    -0.05 (-0.06%)
     
  • GOLD FUTURES

    2,332.00
    -10.10 (-0.43%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • Bitcoin GBP

    53,440.27
    -244.30 (-0.46%)
     
  • CMC Crypto 200

    1,433.77
    +19.01 (+1.34%)
     
  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     
  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     

Antibody Drug Conjugate Market Research Report by Mechanism of Action, by Drugs, by Technology, by Application, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Antibody Drug Conjugate Market Research Report by Mechanism of Action (CD30 Antibodies and HER2 Antibodies), by Drugs (Adcetris and Kadcyla), by Technology, by Application, by End User, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

New York, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antibody Drug Conjugate Market Research Report by Mechanism of Action, by Drugs, by Technology, by Application, by End User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06207382/?utm_source=GNW

The Global Antibody Drug Conjugate Market size was estimated at USD 3,785.23 million in 2020 and expected to reach USD 4,378.75 million in 2021, at a CAGR 16.04% to reach USD 10,727.58 million by 2027.

Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Antibody Drug Conjugate to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Mechanism of Action, the market was studied across CD30 Antibodies and HER2 Antibodies.

Based on Drugs, the market was studied across Adcetris and Kadcyla.

Based on Technology, the market was studied across Cleavable Linker, Linkerless, and Non-cleavable Linker.

Based on Application, the market was studied across Blood Cancer, Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma, and Urothelial Cancer & Bladder Cancer.

Based on End User, the market was studied across Academic Research Institutes, Biopharmaceutical Companies, Biotechnology Companies, Hospitals, Others, and Specialized Cancer Centers.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antibody Drug Conjugate Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antibody Drug Conjugate Market, including Abbvie Inc., ADC Therapeutics, Agensys, Inc., Astellas Pharma, AstraZeneca, Bayer AG, Celldex Therapeutics Inc., Concortis Biotherapeutics, Daiichi Sankyo Company Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Immunomedics Inc., Novartis AG, Oxford BioTherapeutics, Pfizer, Inc., Sanofi S.A., Seagen, Inc., Seattle Genetics Inc., Synthon Holding B.V., and Takeda Pharmaceutical Company Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Antibody Drug Conjugate Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antibody Drug Conjugate Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antibody Drug Conjugate Market?
4. What is the competitive strategic window for opportunities in the Global Antibody Drug Conjugate Market?
5. What are the technology trends and regulatory frameworks in the Global Antibody Drug Conjugate Market?
6. What is the market share of the leading vendors in the Global Antibody Drug Conjugate Market?
7. What modes and strategic moves are considered suitable for entering the Global Antibody Drug Conjugate Market?
Read the full report: https://www.reportlinker.com/p06207382/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001